← Guides

Semaglutide vs Tirzepatide: how they differ

Semaglutide and tirzepatide are two of the most talked-about metabolic drugs of recent years. Both are prescription medications approved by the FDA and the EMA — not supplements or 'research peptides.' This guide compares them at a purely educational level: how they are alike and how they differ in mechanism, the brand names they are sold under, their approved indications and the clinical programs behind each. It includes no dosing guidance and no figures beyond those found in their own drug information, and it is not medical advice. Any use of these drugs is a matter for a healthcare professional assessing the individual case.

The key point: single receptor versus dual agonism

The central biological difference between the two is how many receptors they activate. Semaglutide is a selective GLP-1 receptor agonist: it mimics glucagon-like peptide-1, an incretin hormone that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and acts on appetite centers. Tirzepatide goes a step further: it is the first approved dual agonist, activating both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, a second incretin hormone. The design idea is that engaging both pathways at once combines their metabolic effects. Both molecules share a common structural device — a fatty-acid side chain that promotes albumin binding — which extends their half-life and allows once-weekly dosing. This is a difference of mechanism, not of category: both are synthetically manufactured peptide analogs of incretin hormones, not 'experimental peptides.'

Brands, indications and clinical programs

A common source of confusion is the brand names, because each molecule is sold under different brands depending on the indication. Semaglutide is marketed as Ozempic and Rybelsus for glycemic control in type 2 diabetes, and as Wegovy for chronic weight management. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for weight. It is the same active ingredient under different names; the brand signals the approved indication and the presentation, not a different molecule. On the evidence side, each drug rests on its own phase 3 trial program: semaglutide on Novo Nordisk's STEP (obesity/overweight) and SUSTAIN (type 2 diabetes) programs, and tirzepatide on Eli Lilly's SURMOUNT (obesity) and SURPASS (type 2 diabetes) programs. Head-to-head trials between the two also exist; their specific results belong to each drug's information and the original publications, and interpreting them is the province of a healthcare professional, not of an educational guide.

Approved, supervised drug versus the gray 'research' market

This is the single most important distinction in the whole comparison, and it applies equally to both molecules. Semaglutide and tirzepatide are both genuine prescription medications, approved by the FDA and the EMA, requiring a prescription and medical supervision precisely because they have a narrow margin between effective dosing and intolerance (mainly gastrointestinal) and relevant contraindications. Against that, a gray market has emerged selling 'research use only' or compounded versions outside that regulatory framework. Those products are not approved for human use, carry no quality assurance and bring additional, unquantified risks: uncertain dosing accuracy, impurities, incorrect salt forms (for example semaglutide sodium or acetate, which are not the approved drug's form) and no clinical supervision to manage side effects or contraindications. Regulators have issued specific warnings about adverse events linked to these products, with particular focus on tirzepatide given its greater structural complexity and the periodic shortages that have fed its parallel market. Master of Peptides is an educational project: it explains these drugs, it does not sell them or encourage obtaining them outside a prescription.

Safety profile: what they share

Beyond mechanism, the two drugs share much of their safety profile because they belong to the same family of incretin-based therapies. The most frequent adverse effects documented in trials are gastrointestinal — nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite — generally dose-dependent and most pronounced during the escalation phase. Both carry a boxed warning for thyroid C-cell tumors based on rodent studies (human relevance unconfirmed; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2), and both have documented risks of acute pancreatitis and gallbladder disease. These overlaps are another reason neither is a candidate for self-experimentation: managing these risks, and deciding whether a drug is appropriate for a given person, requires individual medical assessment.

Frequently asked questions

Is tirzepatide 'better' than semaglutide?

That is not a question an educational guide can answer with a yes or no. They are drugs with different mechanisms (GLP-1 agonism versus dual GIP/GLP-1 agonism), their own clinical programs and safety profiles that largely overlap. Head-to-head trials exist, but judging which is more appropriate for a specific person depends on their clinical situation and is a matter for a healthcare professional, not a general comparison.

Are Ozempic, Wegovy, Mounjaro and Zepbound different drugs?

They are four brands corresponding to only two active ingredients. Ozempic, Rybelsus and Wegovy are semaglutide; Mounjaro and Zepbound are tirzepatide. Within each molecule, the brand signals the approved indication and the presentation (for example, glycemic control versus weight management), not a different substance.

Can I buy 'research' semaglutide or tirzepatide to try them?

Both are approved prescription medications requiring a prescription and medical supervision. The 'research use only' or compounded versions circulating outside that framework are not approved for human use, lack quality assurance and have been the subject of regulatory warnings over uncertain dosing, impurities and incorrect forms. This guide is educational; it does not encourage the use of those products or offer medical advice.

✓ Last reviewed · 2026-07-24